TCRR
$19.99
Tcr2 Therapeutics
$.59
3.04%
TCRR
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.52)
Revenue:  $0.00 Mil
Tuesday
Nov 10
6:45 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when TCRR reports earnings?
Beat
Meet
Miss

Where is TCRR's stock price going from here?
Up
Flat
Down
Stock chart of TCRR
Analysts
Summary of analysts' recommendations for TCRR
Score
Grade
Pivots
Resistance
$22.12
$21.38
$20.68

$19.94

Support
$19.24
$18.50
$17.80
Tweet
Growth
Description
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. Its product candidate includes TC-210, TC-220, TC-410, TC-110 and TC-310 which are in clinical stage. TCR2 Therapeutics Inc. is based in Cambridge, Massachusetts.